HOME >> MEDICINE >> NEWS
VCR - First implant in Europe

Ventracor Limited (ASX:VCR) today announced the first European implant of its leading heart assist system.

Ventracor Chief Executive Officer, Colin Sutton PhD, said "Surgeons at Papworth Hospital in the United Kingdom performed the procedure at the weekend.

"The first implant in Europe is a significant step for the company as it clearly demonstrates the clinical excitement surrounding the potential of the VentrAssistTM left ventricular assist system (LVAS).

Chief Medical Investigator at Papworth Dr Steven Tsui said "The operation went according to plan and our patient has been stable during the last 24 hours. Technically, the VentrAssist is easier to implant than many earlier generations of ventricular assist devices. The small size of the pump means that the operation is less traumatic for the patient," Dr Tsui said.

Dr Sutton said participation by Dr Stephen Tsui and his colleagues at Papworth added to the trial's stature and would further accelerate patient enrolment in the CE Mark Trial.

"Over the last couple of weeks, we have implanted seven patients culminating with our first implant outside Australia.

"Ventracor has now implanted the VentrAssist in 23 patients including (nine as part of the pilot trial) and each implant adds to our clinical knowledge and enhances the robust and repeatable patient care protocols used by clinicians to obtain the best results for our patients," Dr Sutton said.

He added Ventracor would carefully expand the number of European hospitals participating in the trial to accelerate acquisition of clinical evidence to support a successful application for European regulatory approval.

"Rikshospitalet in Oslo, Norway is ready to enrol its first patient and we recently met with several leading German heart transplant centres which have all expressed strong interest in participating in our trial program," Dr Sutton said.


'"/>

Contact: Andrew Geddes
61-2-9406-3086
Research Australia
25-May-2005


Page: 1

Related medicine news :

1. First of its kind report on how children with brain tumors perform at school
2. First clinical trial of gene therapy for childhood blindness
3. First nationwide child health and air pollution study commences
4. First step in developing heart hormone-based pill to control high blood pressure
5. First greenhouse gas animations produced using Envisat SCIAMACHY data
6. First ozone and nitrogen dioxide measurements from MetOp-A
7. First-degree fetal heart block may be reversible
8. 10 outstanding scientists chosen as First Environmental Health Science Fellows
9. First-time mothers at increased risk for postpartum mental disorders
10. Transforming knowledge into economic benefits -- EPSRCs First Knowledge Transfer Challenge Awards
11. First Quantum Grant to fund stem cell repair of damage from stroke

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VCR First implant Europe

(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: